Kidney and dialysis最新文献_第9页

When Is Arteriovenous Fistula Dangerous for Hemodialysis Patients? 什么时候动静脉瘘对血液透析患者有危险?

Kidney and dialysis Pub Date : 2022-02-14 DOI: 10.3390/kidneydial2010010

J. Malík

引用次数: 1

Peritoneal Dialysis and the Role of Exercise Training Interventions 腹膜透析和运动训练干预的作用

Kidney and dialysis Pub Date : 2022-02-11 DOI: 10.3390/kidneydial2010007

O. Iyasere, H. Young, J. Burton

引用次数: 1

Reflections on the KDIGO Definition of Acute Kidney Injury and Its Integration in the Concept of Acute Diseases and Disorders and Chronic Kidney Diseases KDIGO对急性肾损伤的定义及其与急性疾病和慢性肾脏疾病概念整合的思考

Kidney and dialysis Pub Date : 2022-02-11 DOI: 10.3390/kidneydial2010008

N. Lameire

{"title":"Reflections on the KDIGO Definition of Acute Kidney Injury and Its Integration in the Concept of Acute Diseases and Disorders and Chronic Kidney Diseases","authors":"N. Lameire","doi":"10.3390/kidneydial2010008","DOIUrl":"https://doi.org/10.3390/kidneydial2010008","url":null,"abstract":"Acute kidney injury (AKI) describes a heterogeneous group of conditions, without specification of their etiology and diagnosed only by indirect markers of glomerular filtration rate (GFR), such as serum creatinine and urine output. Bedside estimation of GFR and detection of structural alterations with novel biomarkers, and stress tests have more recently been developed. These novel findings should probably be included in future AKI definitions. Chronic kidney disease (CKD) is defined by abnormalities in kidney function and structure that persist over >3 months and is classified according to cause, GFR, and albuminuria. Acute kidney disease (AKD) is the term representing patients with abnormalities of function and structure with a duration of ≤3 months that fall outside the definitions of AKI or CKD. Since AKI is by definition also AKD, 2 types of AKD have been proposed, one with and one without AKI. AKD without AKI is common, often undetected, occurs frequently in the outpatient population and shows increased risk of CKD, ESKD and mortality. Alternatively, AKD has also been defined as the period of incomplete recovery following an AKI episode, the latter limited for the duration of 7 days. This contribution discusses the pros and cons of the existence of these 2 definitions of AKD.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42887052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Why Does Vascular Access Dysfunction Occur despite Brachial Artery Blood Flow Being Higher than Preset Blood Flow? 为什么尽管肱动脉血流量高于预设血流量，血管通路仍会出现功能障碍？

Kidney and dialysis Pub Date : 2022-01-14 DOI: 10.3390/kidneydial2010005

Jun-ichi Ono, Takushi Oiwa, Y. Ogasawara, S. Mochizuki

{"title":"Why Does Vascular Access Dysfunction Occur despite Brachial Artery Blood Flow Being Higher than Preset Blood Flow?","authors":"Jun-ichi Ono, Takushi Oiwa, Y. Ogasawara, S. Mochizuki","doi":"10.3390/kidneydial2010005","DOIUrl":"https://doi.org/10.3390/kidneydial2010005","url":null,"abstract":"Background: In recent years, many reports have investigated the usefulness of brachial artery blood flow (BAF) measured by ultrasonography as an evaluation index for the vascular access (VA) stenosis of hemodialysis patients. However, the mechanism of VA dysfunction, despite BAF being higher than the preset blood flow, has not been clarified to date. Methods: The relationship between actual blood-removal flow and recirculation rate with decreasing VA flow was examined using a VA flow path model and pure water as a model fluid. The blood-flow rate was set at 180 mL/min, and the set VA flow rate was lowered stepwise from 350 to 50 mL/min. VA flow rate, blood-removal flow rate, and flow waveform measured between two needle-puncture sites were recorded, and then the actual blood-removal flow rate and recirculation rate were calculated. Results: Recirculation was observed at a VA flow rate < 300 mL/min. The recirculation was due to the VA flow rate, which was transiently reduced to the level below the blood-removal flow rate, resulting in backflow. In contrast, no decrease in the actual blood-removal flow rate was observed. Conclusion: It is suggested that the mechanism of the VA dysfunction, despite the BAF being higher than the preset blood-flow rate, was due to the diastolic BAF being lower than the blood-removal flow rate.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48595928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Antisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease 反义寡核苷酸:慢性肾脏疾病的潜在治疗干预

Kidney and dialysis Pub Date : 2022-01-10 DOI: 10.3390/kidneydial2010004

Yalin Li, Yuqin Tan, Rui Zhang, Tao Wang, N. Na, T. Zheng, R. Veedu, Suxiang Chen

{"title":"Antisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease","authors":"Yalin Li, Yuqin Tan, Rui Zhang, Tao Wang, N. Na, T. Zheng, R. Veedu, Suxiang Chen","doi":"10.3390/kidneydial2010004","DOIUrl":"https://doi.org/10.3390/kidneydial2010004","url":null,"abstract":"Chronic kidney disease (CKD) is a global public health issue that places an increasing burden on the healthcare systems of both the developed and developing countries. CKD is a progressive and irreversible condition, affecting approximately 10% of the population worldwide. Patients that have progressed to end-stage renal disease (ESRD) require expensive renal replacement therapy, i.e., dialysis or kidney transplantation. Current CKD therapy largely relies on the use of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs). However, these treatments by no means halt the progression of CKD to ESRD. Therefore, the development of new therapies is urgently needed. Antisense oligonucleotide (ASO) has recently attracted considerable interest as a drug development platform. Thus far, eight ASO-based drugs have been granted approval by the US Food and Drug Administration for the treatment of various diseases. Herein, we review the ASOs developed for the identification of CKD-relevant genes and/or the simultaneous development of the ASOs as potential therapeutics towards treating CKD.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42179518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and Factors Associated with Opioid Prescription in Swiss Chronic Hemodialysis Patients 瑞士慢性血液透析患者阿片类药物处方的患病率及相关因素

Kidney and dialysis Pub Date : 2022-01-02 DOI: 10.3390/kidneydial2010003

Clémence Hennebel, Valérie Vilmont, A. Cherpillod, D. Fumeaux, F. Fakhouri, F. Livio, M. Burnier, M. Pruijm

{"title":"Prevalence and Factors Associated with Opioid Prescription in Swiss Chronic Hemodialysis Patients","authors":"Clémence Hennebel, Valérie Vilmont, A. Cherpillod, D. Fumeaux, F. Fakhouri, F. Livio, M. Burnier, M. Pruijm","doi":"10.3390/kidneydial2010003","DOIUrl":"https://doi.org/10.3390/kidneydial2010003","url":null,"abstract":"Pain is a common symptom in patients on chronic hemodialysis (HD) but the prevalence of opioid prescriptions in this population has been poorly studied outside the United States. This study assesses the prevalence of opioid prescription in two Swiss dialysis centers. Prescriptions and clinical characteristics were retrospectively retrieved from the medical records of patients on HD for at least six months, treated at Lausanne University Hospital (academic center, AC), and the private center Clinique Cecil (PC) for the study. A total of 117 patients were included; 29.1% received at least one opioid prescription during the study period. Significantly more patients received an opioid prescription in the AC (39.1%) than in the PC (14.6%, p = 0.004). Univariate logistic regression analysis showed that center (Odds Ratio (OR) 3.76; Confidence Interval (CI) 1.48–9.6; p = 0.006), neuropathic pain (OR 2.99; CI 1.28–6.98; p = 0.011), benzodiazepine prescription (OR 2.72; CI 1.14–6.46; p = 0.024), polyneuropathy (OR 2.71; CI 1.14–6.46; p = 0.024) and amputation (OR 4.23; CI 1.1–16.1; p = 0.034) were associated with opioid prescription. The center was the only independent predictive factor in the multivariate analysis. Our results show that opioids are regularly prescribed to Swiss dialysis patients, although important differences exist between centers. The latter finding might suggest that opioid prescribing is more related to the prescriber than to the patient’s condition, but larger-scale studies are necessary to confirm this.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48799219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What Is the Optimal Sodium Concentration in the Dialysate? 透析液中钠的最佳浓度是多少？

Kidney and dialysis Pub Date : 2021-12-31 DOI: 10.3390/kidneydial2010002

Salvador López-Gil, M. Madero

引用次数: 0

How Would You Prescribe the Dialysate Sodium Concentration for Your Patients? 您将如何为您的患者开具透析液钠浓度处方？

Kidney and dialysis Pub Date : 2021-12-23 DOI: 10.3390/kidneydial2010001

F. Port

引用次数: 1

What Is the Optimal Dialysate Sodium Concentration? 透析液钠的最佳浓度是多少？

Kidney and dialysis Pub Date : 2021-12-14 DOI: 10.3390/kidneydial1020022

E. Lindley, J. Tattersall